Key Takeaways
- • Kedrion Biopharma is exploring a €2 billion debt financing that could partially fund a shareholder dividend, according to Bloomberg citing unnamed sources familiar with private discussions.
- • The Italian blood plasma therapies specialist has been in talks with private credit lenders; however, no transaction has been finalized and the company may ultimately forgo the financing.
- • Kedrion, acquired by Permira and co-investors including Abu Dhabi Investment Authority in 2022, generates over €1.5 billion in annual revenue globally.
- • The potential transaction reflects broader trends among private equity-backed companies leveraging debt markets not only for acquisitions and growth but also for capital returns to shareholders.
- • Private credit managers are actively competing to deploy capital amid a subdued M&A market, making dividend-backed financings an increasingly attractive deployment opportunity.
Summary
Kedrion Biopharma, the Italian blood plasma therapies specialist, is exploring a debt raise of approximately €2 billion that could be used in part to fund a dividend payment to shareholders, according to Bloomberg reporting based on conversations with unnamed sources familiar with the matter. The company has been in discussions with private credit lenders regarding potential financing, though the talks remain confidential and no transaction has been concluded. Kedrion has made clear that it could ultimately decide against pursuing the debt issuance.
Kedrion was acquired by Permira and a consortium of co-investors, including Abu Dhabi Investment Authority, in 2022. The company generates more than €1.5 billion in revenue globally and is a specialist in plasma-derived therapeutic products. Both Permira and Kedrion declined to provide substantive comment on the financing discussions, citing the confidential nature of the negotiations.
The potential transaction underscores a strategic shift among private equity-backed companies seeking to deploy debt not solely for acquisitions and organic growth initiatives but increasingly for shareholder distributions. The financing exploration comes at a time when private credit managers face a relatively subdued mergers and acquisitions market, prompting competition among lenders to identify yield-generating deployment opportunities. Dividend-backed debt financings have emerged as a viable avenue for capital repatriation in environments where traditional exit opportunities remain limited, allowing portfolio companies to satisfy investor return expectations while maintaining operational continuity.
Kedrion was acquired by Permira and a consortium of co-investors, including Abu Dhabi Investment Authority, in 2022. The company generates more than €1.5 billion in revenue globally and is a specialist in plasma-derived therapeutic products. Both Permira and Kedrion declined to provide substantive comment on the financing discussions, citing the confidential nature of the negotiations.
The potential transaction underscores a strategic shift among private equity-backed companies seeking to deploy debt not solely for acquisitions and organic growth initiatives but increasingly for shareholder distributions. The financing exploration comes at a time when private credit managers face a relatively subdued mergers and acquisitions market, prompting competition among lenders to identify yield-generating deployment opportunities. Dividend-backed debt financings have emerged as a viable avenue for capital repatriation in environments where traditional exit opportunities remain limited, allowing portfolio companies to satisfy investor return expectations while maintaining operational continuity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.